NEW YORK (GenomeWeb News) - An investment banks today upgraded Invitrogen’s stock despite missed second-quarter estimates and revised forecasts.
 
An analyst at Banc of America Securities upgraded the shares to “Buy” from “Neutral” and said the company “will begin to benefit” from the two-year investment in research and development and facility expansions.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.